From the Montreal Gazette:
GlaxoSmithKline Plc, the world's second-biggest biopharma group, said yesterday Quebec will become the hub of its North American vaccine research and manufacturing operations, lifting the province's ambition to become a leader in life sciences.
GSK is investing $50 million of its own money to upgrade and expand its Laval vaccines research labs acquired along with a big Quebec City vaccines manufacturing plant in the $1.7-billion takeover of ID BioMedical in 2005.
"The Laval operation is being designated the North American HQ of our innovative vaccines division, the Belgium-based GSK Biologicals, and the administrative centre," said Paul Lucas, CEO of GlaxoSmithKline Canada, GSK's main Canadian arm based in Mississauga, Ont. ...more
Wednesday, June 13, 2007
GlaxoSmithKline makes Quebec the hub of its vaccine research and manufacturing
Labels:
GlaxoSmithKline,
Quebec
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment